-

IFF Provides Update on Evolution of Board of Directors

NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF) today outlined the recent changes to its Board of Directors, consistent with its plans to evolve its Board in line with best-in-class corporate governance standards, announced in connection with its long-term strategic and financial vision on Dec. 7, 2022.

  • New Board Chair: Roger W. Ferguson, Jr., experienced IFF Board member, has been named Chair of the IFF Board as of the 2023 Annual Shareholder Meeting. He will succeed Dale F. Morrison, who has been a member of the IFF Board since 2011, most recently serving as Chair since 2022. Morrison has notified IFF of his intent to retire from the Board as of the 2023 Annual Shareholder Meeting due to health reasons;
  • Board Appointments: Mark J. Costa, Dawn Willoughby and Gary Hu have been appointed to the IFF Board; and
  • Board Retirements: Michael Ducker, Ilene Gordon and Kare Schultz have retired as IFF directors.

These changes will result in the Board reducing its size to no more than 10 IFF directors and one Icahn Capital designee director by the 2023 Annual Shareholder Meeting.

“It has been a delight and honor to serve on the IFF Board over the past 12 years, and most recently as Chair of the Board during this transformational period,” said Morrison. “IFF is a leader in its industry, who has built a world-class portfolio, and a robust R&D pipeline to be a premier partner to its customers. I’m proud of the great strides the company has taken at the nexus between creativity and science, and though it is time for me to take a step back and focus on my health, I’m eager to see IFF accelerate ahead in the years to come.”

“We are very grateful for the years of tremendous contributions made by Dale, Ilene, Michael and Kare to help build upon IFF’s strong foundation and guide its future success,” said Ferguson. “In particular, Dale’s leadership as Chair over the past year was pivotal in the development of our refreshed strategic plan and we thank him for his service to IFF. As we progress along our strategic transformation journey, we look forward to welcoming Mark, Dawn and Gary and benefitting from their insights and relevant expertise.”

Mr. Ferguson continued, “The IFF Board and management team remain committed to the successful execution of the next phase of IFF’s strategic transformation, meeting the evolving needs of our customers and maximizing the Company’s long-term profitable growth potential.”

Welcome to IFF 
At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter , Facebook, Instagram, and LinkedIn.

© 2023 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.

Contacts

Media Relations:
Paula Heinkel
332.877.5339
Media.request@iff.com

Investor Relations:
Michael Bender
212.708.7263
Investor.Relations@iff.com

IFF

NYSE:IFF

Release Versions
$Cashtags

Contacts

Media Relations:
Paula Heinkel
332.877.5339
Media.request@iff.com

Investor Relations:
Michael Bender
212.708.7263
Investor.Relations@iff.com

More News From IFF

IFF and Kemira Form Joint Venture To Produce Sustainable Biobased Materials at Scale

NEW YORK--(BUSINESS WIRE)--IFF (NYSE:IFF) and Kemira announced the formation of Alpha Bio, a joint venture aimed at commercial-scale production of renewable biobased materials. With an investment of approximately €130 million, the Alpha Bio facility will start production in late 2027, converting up to 44,000 MT of plant sugars to bioproducts, including high-performance biopolymers for use in various applications, such as home and personal care and industrial solutions. Alpha Bio’s production wi...

IFF Pharma Solutions Brings Next-Gen Excipient Innovations to CPHI Japan 2025

TOKYO--(BUSINESS WIRE)--IFF (NYSE:IFF) Pharma Solutions will showcase its cutting-edge excipient technologies at CPHI Japan 2025. The IFF Pharma Solutions team will highlight its innovations in oral disintegrating tablets (ODTs), controlled-release formulations, and novel complex formulations at booth 5K-21, Tokyo Big Sight East Halls 4-6, April 9-11. “IFF Pharma Solutions is committed to redefining drug delivery through material science innovation,” said Frank Zhao, commercial leader, IFF Phar...

IFF Declares Dividend for First Quarter 2025

NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on April 11, 2025 to shareholders of record as of March 21, 2025. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—ad...
Back to Newsroom
  1. There was an issue with the authorization server. Please contact support if the issue persists.